Article: Health Plans Wary of Biosimilars Despite Potential for Lower Costs | AMCP 2024

2024-05-17T14:06:07+00:00Thought Leadership|

You might be surprised by the biggest operational barrier for biosimilars. But with a lower price than its brand-name reference products, would the inconvenience be worth the reward? With a survey of 25 health plan stakeholders, Dan Danielson, Cynthia Miller and Christopher Terrone discover more than half of the participants feel confident their organization can switch to biosimilars. So, why aren’t they? Find out in their recent conversation with Managed Healthcare Executive.

Read the Article Here!

Article: AI-powered real-world evidence generation for biotechs

2024-05-16T13:26:54+00:00Thought Leadership|

In an ever-evolving biopharma landscape, the quest for real-world evidence (RWE) shines as a guiding light, offering valuable insights into patient outcomes and treatment effectiveness. But what happens when resource constraints cast shadows on this path of discovery? Precision Value & Health’s Ross Maclean sits down with Christophe Segalini and Alexander Büsser to tackle this question head-on and explore how small biotechs are navigating these challenges with innovative strategies and leveraging technology to redefine RWE generation.

Read the Article Here!

Article: A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV plus test strategy for the diagnosis of influenza-like illnesses

2024-05-16T20:41:04+00:00Thought Leadership|

Influenza-like illnesses affect millions each year in the United States. Determining definitively the cause of symptoms is important for patient management. Our Precision experts Emily Boller, Research Scientist, Shawn Davies, Associate Director, Cynthia Miller, VP, Director, Access Experience Team, and Ivar Jensen, Vice President – HEOR Consulting, joined forces with Jordan Chase and Anne Beubrun to look at the data and develop a cost-consequence model demonstrating the clinico-economic impacts of implementing PCR testing with Xpert Xpress compared to current testing strategies. They found The Xpert Xpress CoV-2/Flu/RSV plus enables targeted reliable test results for patients with acute respiratory symptoms resulting in appropriate and efficient testing and treatment.

Read the Article Here!

Video: This Medical Moment

2024-05-16T20:46:51+00:00News, Thought Leadership|

Are you looking for new ways to get your pharma brand in front of your critical HCP targets? Consider tapping into digital opinion leaders (DOLs). “With DOLs, there’s a notable increase in interactivity and back-and-forth discussions creating a ripple effect of their influence,” says Read Roberts, PRECISIONscientia’s Director of KOL Data Solutions. Watch the latest episode of This Medical Moment as Read delves into the transformative power of DOLs in the pharma industry.


Load More Posts